Home Newsfeeds Keybanc Maintains Overweight on Welltower OP, Lowers Price Target to $80

Keybanc Maintains Overweight on Welltower OP, Lowers Price Target to $80

Keybanc analyst Todd Thomas maintains Welltower OP (NYSE:WELL) with a Overweight and lowers the price target from $95 to $80.

byBenzinga Newsdesk

October 10, 2022

1 minute read

Keybanc analyst Todd Thomas maintains Welltower OP (NYSE:WELL) with a Overweight and lowers the price target from $95 to $80.

Planet 13’s Cannabis Superstore And Florida Expansion: Is A Merger In The Air?

By Nicolas Jose Rodriguez

Today, 4:57 PM

Equity research firm Zuanic & Associates initiates coverage of Planet 13 Holdings Inc. (OTC: PLNHF) with an Overweight rating, highlighting that the stock's valuation doesn't fully capture the potential of its unique and scalable superstore concept.

PLNHF

Analyst Ratings

6 Analysts Have This to Say About Jefferies Financial Gr

By Benzinga Insights

September 6, 9:00 AM

Within the last quarter, Jefferies Financial Gr (NYSE:JEF) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

JEF

iMessage Now Seamlessly Works On Android Devices With This App

By Ananya Gairola

December 6, 9:20 AM

Messaging startup Beeper has launched Beeper Mini, an Android app that reverse-engineers Apple's iMessage, enabling Android users to send blue-bubble messages to Apple devices without requiring login details or compromising security, bridging the gap between Android and iOS messaging platforms.

AAPL

Aura Biosciences To Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma At AAO 2023

By Benzinga Newsdesk

October 31, 4:44 PM

Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from

AURA

Keybanc Maintains Overweight on Welltower OP, Lowers Price Target to $80

Related Posts

Planet 13’s Cannabis Superstore And Florida Expansion: Is A Merger In The Air?

6 Analysts Have This to Say About Jefferies Financial Gr

iMessage Now Seamlessly Works On Android Devices With This App

Aura Biosciences To Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma At AAO 2023